葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

未开盘 11-21 16:00:00 EST

33.70

+0.35

+1.05%

盘后33.72

+0.02+0.06%

19:10 EST

最高33.70	最低33.18	成交量703.06万
今开33.40	昨收33.35	日振幅1.57%
总市值687.56亿	流通市值676.70亿	总股本20.40亿
成交额2.35亿	换手率0.35%	流通股本20.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":33.7,"timestamp":1732222800000,"preClose":33.35,"halted":0,"volume":7030641,"hourTrading":{"tag":"盘后","latestPrice":33.72,"preClose":33.7,"latestTime":"19:10 EST","volume":108529,"amount":3657415.1968,"timestamp":1732234253746},"delay":0,"floatShares":2007999999,"shares":2040249850,"eps":1.629535,"marketStatus":"未开盘","marketStatusCode":0,"change":0.35,"latestTime":"11-21 16:00:00 EST","open":33.4,"high":33.7,"low":33.175,"amount":235339106.91735002,"amplitude":0.015742,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.629535,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732266000000},"adr":1,"listingDate":977893200000,"adjPreClose":33.35,"adrRate":2,"dividendRate":0.045752,"preHourTrading":{"tag":"盘前","latestPrice":33.42,"preClose":33.35,"latestTime":"09:29 EST","volume":88090,"amount":2945064.7847700003,"timestamp":1732199395095},"postHourTrading":{"tag":"盘后","latestPrice":33.72,"preClose":33.7,"latestTime":"19:10 EST","volume":108529,"amount":3657415.1968,"timestamp":1732234253746},"volumeRatio":0.762702,"impliedVol":0.2442,"impliedVolPercentile":0.6389},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"2484169121","title":"金十数据整理：每日美股市场要闻速递（11月20日 周三）","url":"https://stock-news.laohu8.com/highlight/detail?id=2484169121","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484169121?lang=zh_cn&edition=full","pubTime":"2024-11-20 21:29","pubTimestamp":1732109340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE0004086264.USD","IBAT","LU0345770993.USD","LU1098665638.USD","NOK","NVDX","NVDY","3NVD.UK","ATHM","LU2092627202.USD","LU0511384066.AUD","NVDS.UK","IE0009G5SDU7.USD","NVDU","GSK","LU0276348264.USD","SY","0HAF.UK","INTC","NIO.SI","NVDS","LU0225283273.USD","PBC","TSLL","III","SMSN.UK","BK4114","NVDL","LU1935042991.SGD","LU0157215616.USD","NVD3.UK","02518","SNVD.UK","LU0289961442.SGD","GSK.UK","NVDA","YMM","09866","NVD","IE0034235303.USD","2NVD.UK","TSLA","TGT","LU0708995583.HKD","NVDD","NIO","NVD2.UK","EVS.SI","AAPL","IE00B19Z8X17.USD"],"gpt_icon":0},{"id":"2484211569","title":"葛兰素史克(GSK.US)IBAT抑制剂治疗PBC相关胆汁淤积性瘙痒III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2484211569","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484211569?lang=zh_cn&edition=full","pubTime":"2024-11-20 21:05","pubTimestamp":1732107905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月19日，葛兰素史克宣布III期GLISTEN研究取得了积极结果。该研究旨在评估回肠胆汁酸转运蛋白抑制剂Linerixibat治疗原发性胆汁性胆管炎相关的胆汁淤积性瘙痒成人患者的疗效和安全性。PBC是一种罕见的胆道疾病，主要影响女性，如果不进行治疗，可能导致肝脏损伤甚至肝衰竭。Linerixibat是一种口服的IBAT抑制剂，通过抑制胆汁酸的再摄取，旨在从根本上解决胆汁淤积性瘙痒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK.UK","BK4532","PBC","III","BK4588","IBAT","BK4585","BK4007","BK4134","GSK","LU1829250122.USD"],"gpt_icon":0},{"id":"1197873203","title":"特朗普力荐小肯尼迪，医药行业迎来“至暗时刻”？","url":"https://stock-news.laohu8.com/highlight/detail?id=1197873203","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197873203?lang=zh_cn&edition=full","pubTime":"2024-11-20 14:43","pubTimestamp":1732085004,"startTime":"0","endTime":"0","summary":"全球医药股上周五大幅下跌，特朗普宣布提名罗伯特·肯尼迪小出任美国卫生部长的消息令市场动荡不安。小肯尼迪此前公开表示，若担任此职位，他将采取措施打击“大型制药公司”。作为美国卫生部长，小肯尼迪将领导一个庞大的机构，负责从食品安全到医学研究和社会福利等领域的事务。小肯尼迪不仅是一位环保律师，还是一位迎合对美国监管机构缺乏信任群体的公众人物。尽管如此，小肯尼迪能否真正对行业政策产生实质性影响仍需观察。","market":"hk","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDNA","AZN","PFE","GSK"],"gpt_icon":1},{"id":"2484194023","title":"《财富》全球最具影响力的100位商界领袖","url":"https://stock-news.laohu8.com/highlight/detail?id=2484194023","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484194023?lang=zh_cn&edition=full","pubTime":"2024-11-19 21:31","pubTimestamp":1732023060,"startTime":"0","endTime":"0","summary":"　　如何精确衡量一个人的“影响力”？影响力是微妙的，它来之不易却又很容易失去，它从来不会一成不变。除了实现规模增长，这些商界领袖也正在打破行业和地域的壁垒，在全球市场扩大影响力。“最具影响力的商界领袖”榜单的上榜者都有一个共同的特质，那就是他们的言行和财富正在影响着他人的思想和行为。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-11-19/doc-incwrhcc2232185.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-19/doc-incwrhcc2232185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0320765489.SGD","BK4162","LU0070302665.USD","IE00B7KXQ091.USD","IE0002270589.USD","BK4007","BK4207","LU0149725797.USD","USPS","LU0211331839.USD","DEI","BK4559","IE00BJJMRY28.SGD","LU0208291251.USD","BK4521","GSK.UK","BK4550","IE0004445015.USD","IE00BJJMRX11.SGD","HSBC","LU1430594728.SGD","IE00BFSS7M15.SGD","BK4532","BK4194","TPG","BK4135","IE00B7SZLL34.SGD","GSK","IE00B19Z3581.USD","BK4131","LU1829250122.USD","LU2133065610.SGD","LU0061475181.USD","LU2237438978.USD","BK4585","LU2236285917.USD","BK4588","LU1585245621.USD","CIA","UPS","BK4534","IE00BFSS8Q28.SGD","LU0320765646.SGD","IE00B19Z3B42.SGD","LU1074936037.SGD","LU1162221912.USD","BK4223"],"gpt_icon":0},{"id":"2484750961","title":"一周内官宣4笔BD交易！双抗新药赛道火爆，跨国药企砸百亿在华“扫货”","url":"https://stock-news.laohu8.com/highlight/detail?id=2484750961","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484750961?lang=zh_cn&edition=full","pubTime":"2024-11-19 14:17","pubTimestamp":1731997033,"startTime":"0","endTime":"0","summary":"本文来源：时代财经 作者：李傲华双抗赛道日渐升温。11月18日，橙帆医药宣布与Avenzo Therapeutics达成一项全球战略合作协议，橙帆医药将授予Avenzo在全球范围内（不包括大中华区）开发、生产和商业化Nectin4/TROP2双特异性抗体偶联药物（ADC），同时保留在大中华区的相关权益。根据约定，橙帆医药可以获得5000万美元的首付...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OGXNPipjng5N0EEVqCMMar7oEn1NEUUoSMX0OgZcn7fE0AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OGXNPipjng5N0EEVqCMMar7oEn1NEUUoSMX0OgZcn7fE0AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241119A052YN00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241119A052YN00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU1057294990.SGD","LU0985320562.USD","SG9999013999.USD","LU0417516571.SGD","LU2461242641.AUD","BK4588","PML","LU1066053197.SGD","09939","LU0289739699.SGD","LU0106261372.USD","GSK","LU1934455863.HKD","BK4080","GSK.UK","LU1061106388.HKD","LU0203347892.USD","LU1116320901.HKD","MRK","LU0053671581.USD","BK4007","SG9999014542.SGD","09926","LU0266013472.USD","SGXZ57979304.SGD","LU1116320737.USD","SG9999015341.SGD","BK4211","LU2112291526.USD","LU2023250504.SGD","IE0002141913.USD","BMS","L","LU0965509010.AUD","IE00BJJMRZ35.SGD","ADC","SG9999001176.SGD","IE00BLSP4239.USD","BK4231","LU1023059063.AUD","BK4534","HR","IE00B1BXHZ80.USD","BK4107","ITT","02162","SG9999001176.USD","LU1934455194.USD","SG9999014559.SGD","PFS"],"gpt_icon":0},{"id":"2484573036","title":"前礼来中国副总裁，加入GSK","url":"https://stock-news.laohu8.com/highlight/detail?id=2484573036","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484573036?lang=zh_cn&edition=full","pubTime":"2024-11-17 09:02","pubTimestamp":1731805364,"startTime":"0","endTime":"0","summary":"近日，葛兰素史克中国宣布，前礼来中国跨生化产品事业部副总裁傅祁越将加入GSK中国特药事业部，担任副总裁及抗感染负责人。傅祁越将直接向GSK中国特药业务负责人张宁汇报工作。在加入GSK之前，她曾在默沙东、拜耳等多家跨国药企任职，并在礼来中国担任多个高管职位。加入GSK后，傅祁越将全面负责抗感染领域艾滋病和肝炎产品组的业务运营，并推动新品长效HIV暴露前预防药物艾普特的加速上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117090758a23ecc82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117090758a23ecc82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GSK.UK","LU0097036916.USD","SG9999014906.USD","SG9999001176.USD","LU0106261372.USD","SG9999015986.USD","LU0640476718.USD","IE0002141913.USD","SG9999015952.SGD","LU0058720904.USD","LU2491049909.HKD","BK4007","LU1093756168.USD","LU1829250122.USD","IE00BJJMRZ35.SGD","LU2237443465.HKD","IE00B2B36J28.USD","SG9999001176.SGD","GB00BDT5M118.USD","BK4516","SG9999015978.USD","LU2361045086.USD","LU0256863811.USD","IE00BK4W5L77.USD","LU2360106947.USD","LU0114720955.EUR","IE00BK4W5M84.HKD","LU0820561909.HKD","LU0708995401.HKD","BK4534","GSK","SG9999018865.SGD","SG9999014880.SGD","LU2063271972.USD","SG9999018857.SGD","LU0882574139.USD","LLY","LU0109391861.USD","IE0004445239.USD","LU0385154629.USD","IE00BJT1NW94.SGD","LU2237443549.SGD","LU0203202063.USD","LU2361044865.SGD","LU2491050071.SGD","SG9999014914.USD","SGXZ81514606.USD","IE00BJLML261.HKD","LU1280957306.USD","LU1127390331.HKD"],"gpt_icon":1},{"id":"2483560167","title":"站在“雪崩”边缘的阿斯利康会成为下一个GSK吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2483560167","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483560167?lang=zh_cn&edition=full","pubTime":"2024-11-16 15:39","pubTimestamp":1731742740,"startTime":"0","endTime":"0","summary":"十年前中国掀起的“反腐风暴”曾让英国制药公司葛兰素史克经历一场剧变。十年后，又一家英国制药公司阿斯利康再次站上“雪崩”的边缘。　　11月15日，阿斯利康中国区总裁王磊已被拘留长达半个月。迄今为止，外界对王被调查的原因仍一无所知。　　相关律师对第一财经记者表示，阿斯利康大范围“骗保案”未针对单位进行立案，有蹊跷之处，而王磊作为阿斯利康中国区“一把手”被拘留，可能是一个开端。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-11-16/doc-incwfyam9015974.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-11-16/doc-incwfyam9015974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0109394709.USD","BK4588","BK4007","LU0320765992.SGD","BK4585","LU0889565916.HKD","LU2456880835.USD","LU2417539215.USD","LU2462157665.USD","LU2236285917.USD","BK4568","GSK.UK","BK4532","LU1829250122.USD","AZN","GSK"],"gpt_icon":0},{"id":"2483543445","title":"特朗普提名小肯尼迪引发市场恐慌 多家疫苗制造商股价连跌两日","url":"https://stock-news.laohu8.com/highlight/detail?id=2483543445","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483543445?lang=zh_cn&edition=full","pubTime":"2024-11-16 10:28","pubTimestamp":1731724124,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4534","BK4550","LU0211331839.USD","LU0225771236.USD","LU1267930490.SGD","LU0047473722.EUR","LU1487256676.USD","AZN.UK","LU2089283258.USD","GSK.UK","LU0757432116.USD","LU0971552673.USD","LU1153584641.USD","LU1989771016.USD","LU2133065610.SGD","IE00B19Z3B42.SGD","LU1228905037.USD","LU1481600234.SGD","LU0158827948.USD","IE0034235071.USD","LU0868494617.USD","LU2112291526.USD","LU0306807586.USD","LU1066053197.SGD","LU1814569148.SGD","159646","LU0963555726.SGD","LU2114397693.USD","LU1400636657.SGD","LU0114720955.EUR","LU0496365809.HKD","LU0823399737.USD","LU1061106388.HKD","LU0077335932.USD","LU0058720904.USD","LU1051770623.HKD","LU0109981661.USD","LU2091194634.USD","IE00BWDBJ516.SGD","LU1880407215.USD","PFE","IE00BLSP4452.SGD","NVO","SG9999002232.USD","BK4588","LU0557290698.USD","LU1880407132.USD","SG9999001176.USD","GSK","03165"],"gpt_icon":0},{"id":"2483630193","title":"GSK(GSK.US)ADC疗法3期临床结果积极 延长难治性癌症患者生命","url":"https://stock-news.laohu8.com/highlight/detail?id=2483630193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483630193?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:38","pubTimestamp":1731631089,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，GSK今日宣布，其抗体偶联药物Blenrep在3期临床试验DREAMM-7的预定中期分析中获得了积极结果。该试验评估了Blenrep联合硼替佐米和地塞米松作为复发或难治性多发性骨髓瘤的二线或更晚期治疗的效果。试验达到了总生存期的关键次要终点，显示出Blenrep联合BorDex与标准治疗方案相比，显著降低了患者死亡风险。Blenrep是一种靶向B细胞成熟抗原的抗体偶联药物，由人源化抗BCMA单克隆抗体与细胞毒性载荷auristatin F通过不可切割的连接子结合而成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK","BK4532","ADC","BK4231","BK4007","LU1829250122.USD","BK4585","BK4588","BK4080","GSK.UK"],"gpt_icon":0},{"id":"2483862840","title":"葛兰素史克抗癌药物Blenrep显著降低死亡风险 有望重获监管批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2483862840","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483862840?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:53","pubTimestamp":1731574430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0971552673.USD","BK4007","LU1202635105.USD","LU0058720904.USD","LU0321505439.SGD","LU0211331839.USD","LU1481600234.SGD","LU1302929846.USD","LU1228905540.USD","GSK.UK","LU0545562505.USD","IE00BWDBJ516.SGD","LU1400636657.SGD","LU0203347892.USD","LU1046248800.SGD","LU0225771236.USD","LU0203345920.USD","BK4532","LU0289739699.SGD","LU0575583348.USD","LU1015430645.USD","LU1400636491.USD","LU1064927863.SGD","LU1645745479.HKD","GSK","LU0225284248.USD","LU0985481810.HKD","LU1487256676.USD","LU1670756490.USD","LU1829250122.USD","LU0109981661.USD","LU1228905037.USD","LU1400636574.HKD","LU0321505868.SGD","BK4585","BK4588","IE0034235071.USD","LU1481599808.USD","LU1035777561.USD","IE00BQJZX424.USD","LU0971552830.HKD","LU1098665638.USD","BK5011"],"gpt_icon":0},{"id":"2483847750","title":"葛兰素史克(GSK.US)抗癌药物Blenrep显著降低死亡风险 有望重获监管批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2483847750","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483847750?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:48","pubTimestamp":1731574109,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英国制药巨头葛兰素史克公司表示，其血液癌症药物在与另一种癌症治疗药物联合使用时，显著降低了癌症患者们死亡风险，进一步提高了将之前被FDA与欧洲药品管理局宣布撤回的抗癌药物Blenrep重新推向市场的前景。葛兰素史克称，Blenrep在与另一种名为BorDex的癌症疗法联合使用时，帮助那些骨髓瘤复发的患者们延长了寿命。今年早些时候，葛兰素史克曾表示，当Blenrep与另一种名为PomDex的癌症治疗药物联合使用时，有助于减缓疾病进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1829250122.USD","BK4588","GSK.UK","BK4585","BK4532","GSK","BK4007"],"gpt_icon":0},{"id":"2481129190","title":"FDA建议停止使用感冒药中常见减充血剂 葛兰素史克(GSK.US)等公司或受影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2481129190","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481129190?lang=zh_cn&edition=full","pubTime":"2024-11-08 18:11","pubTimestamp":1731060706,"startTime":"0","endTime":"0","summary":"然而，FDA的行动只涉及口服给药的苯肾上腺素，不涉及鼻腔喷雾剂。宝洁和葛兰素史克等公司被指控在含有该成分的感冒药上欺骗消费者。FDA目前正在征求公众对这一拟议命令的意见。目前，制药公司可能会继续销售含有口服苯肾上腺素作为减充血剂的药品。消费者保健产品协会在一份声明中表示，“对FDA提议扭转其长期以来对口服苯肾上腺素的看法感到失望”。泰诺生产商Kenvue、葛兰素史克、Haleon和宝洁未立即回应置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK.UK","BK4588","BK4532","BK4585","LU1829250122.USD","BK4007","GSK"],"gpt_icon":0},{"id":"2481928842","title":"专访GSK副总裁、中国疫苗业务负责人李卫东：推动疫苗处方走深走实，深化医防融合","url":"https://stock-news.laohu8.com/highlight/detail?id=2481928842","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481928842?lang=zh_cn&edition=full","pubTime":"2024-11-07 15:30","pubTimestamp":1730964625,"startTime":"0","endTime":"0","summary":"21世纪经济报道季媛媛见习记者李佳英上海报道第七届中国国际进口博览会（以下简称“进博会”）于11月5日至10日在上海如期举行，GSK携多款创新产品、亮点活动再赴进博之约。进博会不仅是“构建新发展格局的窗口”，更是“推动高水平开放的平台”以及“全球共享的国际公共产品”。受益于进博会的溢出效应，GSK多款疫苗产品加速在中国落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411073232625856.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411073232625856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","GSK","BK4585","BK4532","LU1829250122.USD","GSK.UK","BK4588"],"gpt_icon":0},{"id":"2481980452","title":"看跨国药械企业如何用创新方案践行中国承诺 | 聚焦进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2481980452","media":"国际金融报","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481980452?lang=zh_cn&edition=full","pubTime":"2024-11-06 20:02","pubTimestamp":1730894520,"startTime":"0","endTime":"0","summary":"11月5日，第七届中国国际进口博览会在上海国家会展中心正式开幕。本届进博会共有129个国家和地区的3496家展商参加企业展，按照行业类别分布在8个场馆中。在这里，跨国药械企业们带来最新的健康解决方案践行着对中国市场的承诺。自2017年以来诺华已有近40款产品被纳入国家医保目录，在跨国企业中居前列。2023年，诺华创新药物惠及了约7300万中国患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"weixin_highlight","url":"http://mp.weixin.qq.com/s?__biz=MjM5Nzc1NTQ4MA==&mid=2653223993&idx=2&sn=9a296548d0f344e4b6f580e6d99706b0&chksm=bd05730e8a72fa18e5203a9f24dab6e063b317d1e74f746ef67d189e86e53e62f42fec5cb0a7#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5Nzc1NTQ4MA==&mid=2653223993&idx=2&sn=9a296548d0f344e4b6f580e6d99706b0&chksm=bd05730e8a72fa18e5203a9f24dab6e063b317d1e74f746ef67d189e86e53e62f42fec5cb0a7#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0122379950.USD","BK4592","LU0170899867.USD","LU0868494617.USD","IE00BBT3K403.USD","BK4588","IE00B19Z3B42.SGD","LU1066053197.SGD","IE00BLSP4452.SGD","BK4532","PFE","LU1883839398.USD","SG9999011175.SGD","LU0289739699.SGD","BK4550","GSK.UK","BK1574","LU0234572021.USD","BK4581","LU1023059063.AUD","LU1057294990.SGD","LU0321505868.SGD","LU0306806265.USD","IE000M9KFDE8.USD","LU0456855351.SGD","GSK","LU1894683264.USD","SG9999002224.SGD","IE00BLSP4239.USD","BK4568","LU0225771236.USD","BK4007","LU0985481810.HKD","LU0058720904.USD","LU1829250122.USD","LU0321505439.SGD","06978","LU1066051498.USD","BK1161","LU0225284248.USD","IE00B19Z3581.USD","SG9999001176.USD","BK4533","IE0002270589.USD","SG9999001176.SGD","SG9999003800.SGD","BK4534","SG9999013999.USD","BK4585","LU0306807586.USD"],"gpt_icon":1},{"id":"2481150024","title":"（第七届进博会）葛兰素史克中国总经理余慧明：在进博会看到中国未来发展的确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2481150024","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481150024?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:30","pubTimestamp":1730817036,"startTime":"0","endTime":"0","summary":"中新网上海11月5日电(记者樊中华汤彦俊)“进博会让我们外企有了切实的获得感，看得到中国未来发展的确定性。进博会越办越好，企业也越走越快，进博‘溢出效应’是企业感受到的最直接的价值。”5日，第七届中国国际进口博览会(下称“进博会”)开幕，葛兰素史克(下称“GSK”)副总裁、中国总经理余慧明接受中新网记者采访时表示：“依托进博会，我们可以更好地共享中国式现代化的发展机遇。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411053229998013.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411053229998013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","BK4588","BK4532","BK4585","LU1829250122.USD","BK4007","GSK"],"gpt_icon":0},{"id":"2480360721","title":"葛兰素史克2024财年第三财季实现净利润-75.40百万美元，同比减少104.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480360721","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480360721?lang=zh_cn&edition=full","pubTime":"2024-11-04 00:00","pubTimestamp":1730649626,"startTime":"0","endTime":"0","summary":"11月4日，葛兰素史克公布财报，公告显示公司2024财年第三财季净利润为-75.40百万美元，同比减少104.07%；其中营业收入为104.16亿美元，同比增加1.03%，每股基本收益为-0.04美元。从资产负债表来看，葛兰素史克总负债598.19亿美元，其中短期债务37.76亿美元，资产负债比为1.31，流动比率为0.81。机构评级：截至2024年11月4日，当前有16家机构对葛兰素史克目标价做出预测，其中目标均价为46.70美元，其中最低目标价为36.64美元，最高目标价为67.91美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104000041ab9b4e3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104000041ab9b4e3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GSK"],"gpt_icon":0},{"id":"2480514350","title":"成都团队，一款药卖出60亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2480514350","media":"投资界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480514350?lang=zh_cn&edition=full","pubTime":"2024-11-03 19:02","pubTimestamp":1730631743,"startTime":"0","endTime":"0","summary":"又一笔极具标志性的创新药交易诞生。本周，跨国药企葛兰素史克公司（GSK）正式宣布，和恩沐生物达成管线合作协议，将收购其自主研发的三抗药物CMG1A46。根据条款，交易潜在价值最高可达惊人的8.5亿美元（约合人民币60.6亿元）。&nbsp;此次交易的主角恩沐生物，总部位于成都，成立至今融资数亿元，如今却一举收获超20亿元的...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241103A05TT000","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241103A05TT000","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4585","09939","BK4588","06978","BK4077","GSK.UK","SLE","BK1574","BK1515","GSK","BK1161","BK4532","LU1829250122.USD","BK4007"],"gpt_icon":0},{"id":"2480003852","title":"3年市值跌没3000亿，智飞生物“重庆富豪父子”能否力挽狂澜？","url":"https://stock-news.laohu8.com/highlight/detail?id=2480003852","media":"野马财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480003852?lang=zh_cn&edition=full","pubTime":"2024-11-01 18:15","pubTimestamp":1730456137,"startTime":"0","endTime":"0","summary":"HPV疫苗热退温了？      作者 | 于婞      编辑丨武丽娟      来源 | 野马财经      曾经的千亿疫苗巨头，“躺平”的日子要结束了吗？      10月26日，智飞生物三季报....","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OqnLcO-gujyQUjzkNEOuJCpOweWWLNqyrrtZu6CUHxSZEAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OqnLcO-gujyQUjzkNEOuJCpOweWWLNqyrrtZu6CUHxSZEAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241101A07ZE600","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241101A07ZE600","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU0861579265.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU1066051225.USD","LU0234572021.USD","LU1917777945.USD","LU1061106388.HKD","IE00B1BXHZ80.USD","GSK.UK","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4534","LU0211331839.USD","LU1430594728.SGD","LU1585245621.USD","LU1066051498.USD","LU0058720904.USD","BK4559","IE00B4R5TH58.HKD","LU0965509010.AUD","LU1934455194.USD","IE0002141913.USD","LU1066051811.HKD","BK4532","IE000M9KFDE8.USD","LU0320765489.SGD","LU0106261372.USD","BK4007","BK4550","IE00BBT3K403.USD","LU0203347892.USD","IE00BSNM7G36.USD","LU1066053197.SGD","LU0208291251.USD","LU1934455277.USD","LU0965509283.SGD","LU1116320901.HKD","LU0006306889.USD","IE00BFTCPJ56.SGD","IE00BLSP4239.USD","GSK","LU0289739699.SGD","LU0238689110.USD","MRK","LU1093756168.USD","LU0265550946.USD","BK4516","LU0070302665.USD","IE00B2B36J28.USD","IE00BN8TJ469.HKD"],"gpt_icon":0},{"id":"2479510782","title":"美股异动｜葛兰素史克跌超3.8% Q3营收同比下降2%逊预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2479510782","media":"港股那点事","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479510782?lang=zh_cn&edition=full","pubTime":"2024-10-30 22:38","pubTimestamp":1730299080,"startTime":"0","endTime":"0","summary":"格隆汇10月30日｜葛兰素史克(GSK.US)跌超3.8% ，报36.7美元。消息面上，葛兰素史克第三季度营收80.12亿英镑，同比下降2%，低于分析师预期的81亿英镑；扣除部分项目后的每股收益为49.7便士，高于分析师预测的44便士。期内疫苗销售额下降18%至26.5亿英镑。(格隆汇)\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-10-30/doc-incukeat3316253.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-10-30/doc-incukeat3316253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSK"],"gpt_icon":0},{"id":"2479009482","title":"葛兰素史克Q3营收同比下降2%逊预期 疫苗销售额下降18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479009482","media":"港股那点事","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479009482?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:12","pubTimestamp":1730293920,"startTime":"0","endTime":"0","summary":"格隆汇10月30日｜葛兰素史克公布第三季度业绩，营收80.12亿英镑，同比下降2%，低于分析师预期的81亿英镑；扣除部分项目后的每股收益为49.7便士，高于分析师预测的44便士。期内疫苗销售额下降18%至26.5亿英镑。该公司重申2024年调整后每股收益将增长10至12%，核心营业利润将增长11至13%，销售额将增长7至9%。               \n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-10-30/doc-incuixuq0920871.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-10-30/doc-incuixuq0920871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159646","GSK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":-0.0201},{"period":"1month","weight":-0.1132},{"period":"3month","weight":-0.2095},{"period":"6month","weight":-0.2531},{"period":"1year","weight":-0.0426},{"period":"ytd","weight":-0.0907}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由 Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.568182,"avgChangeRate":0.012276},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.003512},{"month":3,"riseRate":0.613636,"avgChangeRate":0.0208},{"month":4,"riseRate":0.666667,"avgChangeRate":0.032721},{"month":5,"riseRate":0.4,"avgChangeRate":-0.008934},{"month":6,"riseRate":0.6,"avgChangeRate":0.011286},{"month":7,"riseRate":0.555556,"avgChangeRate":0.004756},{"month":8,"riseRate":0.577778,"avgChangeRate":0.004428},{"month":9,"riseRate":0.511111,"avgChangeRate":0.004151},{"month":10,"riseRate":0.511111,"avgChangeRate":0.011448},{"month":11,"riseRate":0.466667,"avgChangeRate":0.009403},{"month":12,"riseRate":0.613636,"avgChangeRate":0.014479}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}